MicroRNA-4458 suppresses migration and epithelial–mesenchymal transition via targeting HMGA1 in non-small-cell lung cancer cells
Authors Ma Y, Li X, Chen S, Du B, Li Y
Received 23 August 2018
Accepted for publication 2 December 2018
Published 10 January 2019 Volume 2019:11 Pages 637—649
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr Beicheng Sun
Yu Ma, Xuena Li, Song Chen, Bulin Du, Yaming Li
Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Purpose: Increasing studies have shown that microRNA-4458 (miR-4458) is associated with human cancer progression. However, the molecular mechanism of miR-4458 in non-small-cell lung cancer (NSCLC) remains largely unknown. This study aims to reveal the biological function of miR-4458 in NSCLC.
Materials and methods: The expression of miR-4458 in NSCLC cells was evaluated by qRT-PCR. Cell proliferation and migration assay were carried out in vitro after transfection. A luciferase reporter and Western blot assay were performed to identify the functional target of miR-4458.
Results: The study indicated that miR-4458 was markedly downregulated in NSCLC cells. Overexpression of miR-4458 strongly reduced the proliferation and migration in NSCLC cell lines. In addition, miR-4458 inhibited the progression of migration and epithelial–mesenchymal transition (EMT) through the PI3K/AKT pathway. Luciferase report assay demonstrated that HMGA1 was a target gene for miR-4458.
Conclusion: The results indicate that miR-4458 participated in the process of migration and EMT via directly targeting HMGA1 and miR-4458 might be a potential novel therapeutic target in NSCLC.
Keywords: HMGA1, migration, epithelial–mesenchymal transition, miR-4458, NSCLC
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]